Issue date: 24 Feb 2026
Closing date: 27 Mar 2026
The 252604 trial of the Myeloproliferative Neoplasms Diagnostic Testing programme features MRD sample MPN DT 127.
This sample represents a follow-up sample from a JAK2 p.(Val617Phe) positive myelofibrosis patient post-haematopoeitic stem cell transplant. It requires JAK2 p.(Val617Phe) measurable residual disease (MRD) analysis only. If your laboratory performs JAK2 p.(Val617Phe) MRD analysis using an alternative assay to that used for diagnostic testing, please provide details on the following JotForm pages.
To ensure results are considered appropriately, it is essential that we are aware of your assay details, including the limit of detection (LoD). Participants will not be penalised for failing to detect MRD if appropiate testing is not available. If your laboratory does not perform MRD analysis, it is not compulsory to test this sample.
If you have not tested sample MPN DT 127, or have tested MPN DT 127 using the same assay you employ for diagnostic testing (as described previously in your UK NEQAS LI submission page), please do not complete this survey. These pages are for providing additional details of your JAK2 p.(Val617Phe) MRD assay only.
Testing of MRD samples (including sample MPN DT 127) is not yet subject to performance monitoring. We are working towards accreditation of this aspect of the programme and will communicate progress via future trial coverletters and reports.
Please note that all results for this trial (samples MPN DT 126 and 127), as well as assay details for diagnostic testing, must be submitted as usual via your UK NEQAS LI submission page for this trial: https://hub.ukneqasli.co.uk/SampleEntry/